Loading...
XNASACRS
Market cap268mUSD
Jan 16, Last price  
2.51USD
1D
0.00%
1Q
110.92%
Jan 2017
-90.75%
IPO
-77.29%
Name

Aclaris Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:ACRS chart
P/E
—
P/S
8.60
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
16.23%
Rev. gr., 5y
25.37%
Revenues
31m
+5.03%
00001,683,00010,091,0004,227,0006,482,0006,761,00029,752,00031,249,000
Net income
-88m
L-0.20%
-5,236,000-8,517,000-20,563,000-48,079,000-68,523,000-132,738,000-142,850,000-51,154,000-114,281,000-88,662,000-88,481,000
CFO
-78m
L+15.92%
-4,920,000-7,636,000-20,369,000-34,603,000-54,663,000-100,811,000-96,445,000-38,633,000-52,134,000-67,567,000-78,325,000
Earnings
Feb 25, 2025

Profile

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
URL
https://www.aclaristx.com/
IPO date
Oct 07, 2015
Employees
100
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
31,249
5.03%
29,752
340.05%
Cost of revenue
147,563
114,906
Unusual Expense (Income)
NOPBT
(116,314)
(85,154)
NOPBT Margin
Operating Taxes
(367)
1,754
Tax Rate
NOPAT
(115,947)
(86,908)
Net income
(88,481)
-0.20%
(88,662)
-22.42%
Dividends
Dividend yield
Proceeds from repurchase of equity
26,714
72,710
BB yield
-36.45%
-7.08%
Debt
Debt current
852
684
Long-term debt
426
2,254
Deferred revenue
(1,570)
Other long-term liabilities
9,274
34,670
Net debt
(180,599)
(239,117)
Cash flow
Cash from operating activities
(78,325)
(67,567)
CAPEX
(1,309)
(605)
Cash from investing activities
46,220
12,628
Cash from financing activities
26,706
72,867
FCF
(116,468)
(86,672)
Balance
Cash
119,106
229,813
Long term investments
62,771
12,242
Excess cash
180,315
240,567
Stockholders' equity
(770,901)
(683,211)
Invested Capital
938,206
916,186
ROIC
ROCE
EV
Common stock shares outstanding
69,809
65,214
Price
1.05
-93.33%
15.75
8.32%
Market cap
73,299
-92.86%
1,027,120
24.52%
EV
(107,300)
788,003
EBITDA
(115,451)
(84,357)
EV/EBITDA
0.93
Interest
4,700
Interest/NOPBT